The results confirmed the strong anti-cancer activity of cyclin-dependent kinase 12 and 13 (CDK12/13) inhibitors and the synergistic effect of THZ531 and pathway inhibitors (EGFR, RPTOR, ATRIP) regulated by cancer-related genes on the activity of HGSOC organoids (Cesari et al., 2023). The gene discussed is ATRIP; the disease is cancer.